Longevity Startups: Separating Science From Hype in Due Diligence

Longevity Startups: Separating Science From Hype in Due Diligence

Few sectors combine as much scientific promise and as much marketing noise as longevity. On one side are serious research programmes backed by some of the world's wealthiest investors, such as Altos Labs, which launched in 2022 with around $3 billion, and Alphabet-backed Calico. On the other are clinics, supplements and consumer products making bold claims on thin evidence.

For investors, the challenge is telling the difference. This guide explains the main categories of longevity companies, why regulation makes "treating ageing" unusually hard, and the diligence questions that separate credible science from hype.

1. What Counts as a Longevity Company

• Therapeutics targeting biological mechanisms of ageing, such as cellular senescence, cellular reprogramming, mitochondrial function or inflammation.
• Diagnostics and biomarkers, including tools that estimate biological age or track health risks.
• Preventive health platforms, such as advanced screening, clinics and personalised health programmes.
• Consumer products, including supplements, wearables and wellness services.

These categories carry very different risks, timelines and evidence standards, so they should never be diligenced the same way.

2. The Regulatory Problem

Regulators such as the US Food and Drug Administration do not treat ageing itself as a disease that a drug can be approved to treat. Therapeutics companies therefore need to target a specific disease or condition, such as a particular age-related illness, and prove benefit in clinical trials for that indication.

This matters for investors in three ways:

• The first approval will be narrow, even if the long-term vision is broad.
• Clinical trials for ageing-related outcomes are long and expensive, because they measure changes that happen over years.
• Biomarkers of ageing are not yet accepted endpoints for drug approval, so a company cannot rely on them alone to prove efficacy.

3. Diligence Questions for Therapeutics

• What is the mechanism, and how strong is the evidence? Look for peer-reviewed research, replication by independent labs and results in relevant models.
• What is the first indication? A clear, specific disease target with an established regulatory pathway is essential.
• What are the trial endpoints? They should be outcomes regulators accept, not only biomarker changes.
• How much capital is needed to reach each clinical milestone?
• Who are the scientific founders and advisers, and what is their track record?
• What is the safety profile? Interventions for healthy or pre-symptomatic people face a very high safety bar.

Our guide to how biotech startups get funded covers the broader financing path.

4. Diligence Questions for Consumer and Clinic Models

• Are the claims supported? Marketing claims about extending life or reversing ageing can attract regulatory scrutiny.
• What is the business model? Subscriptions, memberships and testing can generate real revenue, but retention and customer acquisition costs matter.
• Is there medical oversight? Clinics offering interventions need appropriate licensing and clinical governance.
• What is the moat? Brand and data can be defensible; generic supplements usually are not.

5. Red Flags

• Claims to "reverse ageing" based on a single biomarker or small study.
• No clear first indication or regulatory strategy for a therapeutic.
• Science that has not been independently replicated.
• Heavy reliance on celebrity endorsement or influencer marketing.
• Unclear separation between research, clinical services and product sales.

For a broader diligence framework, see how to vet a deal sourced through an investor network.

Frequently Asked Questions

Is longevity a real investment category?

Yes. Serious research and significant capital are behind it, but the field spans rigorous science and unproven consumer offerings, so selectivity is essential.

Why can't a drug be approved to treat ageing?

Because regulators do not currently recognise ageing as a disease indication. Companies target specific age-related conditions instead.

How long do longevity therapeutics take to reach market?

Like other drugs, often many years, with clinical trials representing the largest share of time and cost.

Who invests in longevity?

Biotech venture funds, family offices, high-net-worth individuals with a personal interest, and some pharmaceutical partners.

The Bottom Line

Longevity combines real scientific progress with a large amount of marketing noise. Investors who insist on strong evidence, a clear regulatory path, realistic endpoints and honest capital plans can back credible companies; those who invest on the vision alone risk paying for hype.

Global Capital Network connects investors with life sciences and health opportunities through our events and investor network. Get in touch to learn more.

This article is general information, not medical or investment advice.